Atai's Clinical Results Of R-Ketamine For Depression: Road To Subcutaneous At-Home Administration
Portfolio Pulse from Lara Goldstein
atai Life Sciences (NASDAQ:ATAI) has shared results from its subsidiary Perception Neuroscience’s Phase 1 study of its proprietary R-ketamine compound PCN-101. The study assessed the safety, tolerability and pharmacokinetic profile of PCN-101 delivered subcutaneously compared to intravenous delivery. Results showed that PCN-101 was generally well-tolerated, and no serious adverse events were reported. The study also showed a favorable safety and tolerability profile compared to Johnson & Johnson's (NYSE:JNJ) Spravato.
August 09, 2023 | 8:51 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
The study results of atai Life Sciences' R-ketamine compound PCN-101 showed a more favorable safety and tolerability profile compared to Johnson & Johnson's Spravato, which could potentially impact JNJ's stock negatively.
If a competitor's product shows a more favorable safety and tolerability profile, it could potentially lead to a decrease in the stock price of the company with the less favorable product.
CONFIDENCE 80
IMPORTANCE 70
RELEVANCE 60
POSITIVE IMPACT
atai Life Sciences' Phase 1 study results of its R-ketamine compound PCN-101 show promising safety and tolerability profile, which could potentially boost the company's stock.
Positive clinical trial results often lead to increased investor confidence and can potentially boost a company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100